Abstract
Social anxiety disorder (SAD) is a debilitating disorder, characterized by fear and anxiety in social situations. Evidence suggests that the levels of SAD are rising, in particularly after the COVID-19 pandemic. Serotonin and noradrenaline reuptake inhibitors and cognitive-behavioral therapy are effective treatments for SAD. Nevertheless, a significant number of patients do not respond well to these therapeutic options. During the last years, Cannabis and cannabinoid-containing products have been investigated for the treatment of different neuropsychiatric disorders. Nevertheless, their efficacy for the treatment of anxiety disorders is still a matter of debate. The purpose of this review was to investigate subjective, behavioral, and neurobiological effects of Cannabis and cannabinoids in social anxiety and SAD. A search in the PubMed database for articles published between the years of 2003–2023 was conducted. One hundred and seventeen (117) original studies were identified. After the exclusion criteria, eighteen (18) studies were selected. The studies investigated the effects of the cannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in patients or healthy volunteers submitted to tasks that assessed social anxiety. Results showed that CBD decreases social anxiety, producing an inverted U-shaped curve, with anxiety measurements being reduced at intermediate doses administered orally (300–600 mg), but not at lower or higher doses. THC either reduces (lower doses, 6–7.5 mg) or increases (higher doses) social anxiety measurements. CBD attenuates the anxiogenic effects of THC. The effects of THC and CBD in anxiety are associated to the modulation of fronto-limbic regions. Further clinical trials, conducted with male and female patients and larger cohorts are still necessary to consolidate these results.
Acknowledgments
This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil.
-
Research ethics: Not applicable.
-
Informed consent: Not applicable.
-
Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: There is no conflict of interests.
-
Research funding: This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil.
-
Data availability: Not applicable.
References
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders, 5th ed American Psychiatric Association, Washington, DC.10.1176/appi.books.9780890425596Search in Google Scholar
Andrade, A.K., Renda, B., and Murray, J.E. (2019). Cannabinoids, introception, and anxiety. Pharmacol. Biochem. Behav. 180: 60–73, https://doi.org/10.1016/j.pbb.2019.03.006.Search in Google Scholar PubMed
Appiah-Kusi, E., Petros, N., Wilson, R., Colissi, M., Bossong, M.G., Valmaggia, L., Mondelli, V., McGuire, P., and Bhattacharyya, S. (2020). Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl.) 237: 1121–1130, https://doi.org/10.1007/s00213-019-05442-6.Search in Google Scholar PubMed PubMed Central
Arrais, K.C., Machado-de-Sousa, J.P., Trzesniak, C., Filho, A.S., Ferrari, M.C., Osório, F.L., Loureiro, S.R., Nardi, A.E., Hetem, A.B., Zuardi, A.W., et al.. (2010). Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender. J. Psychiatr. Res. 44: 535–540, https://doi.org/10.1016/j.jpsychires.2009.11.003.Search in Google Scholar PubMed
Ballard, M.E., Bedi, G., and Wit, H. (2012). Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J. Psychopharmacol. 26: 1289–1298.10.1177/0269881112446530Search in Google Scholar PubMed PubMed Central
Bergamaschi, M., Queiroz, R., Chagas, M., Oliveira, D., Martinis, B., Kapczinski, F., Quevedo, J., Roesler, R., Shroder, N., Nardi, A., et al.. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36: 1219–1226, https://doi.org/10.1038/npp.2011.6.Search in Google Scholar PubMed PubMed Central
Bhattacharya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O’Carroll, C.M., Seal, M., Allen, P., et al.. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764–774.10.1038/npp.2009.184Search in Google Scholar PubMed PubMed Central
Bossong, M.G., van Hell, H., Jager, G., Kahn, R.S., Ramsey, N.F., and Jansma, J.M. (2013). The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol. Eur. Neuropsychopharmacol. 23: 1687–1697.10.1016/j.euroneuro.2013.06.009Search in Google Scholar PubMed
Bridgeman, M.B. and Abazia, D.T. (2017). Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T 42: 180–188.Search in Google Scholar
Buke, B., Divrikli, U., Soylak, M., and Elci, L. (2009). On-line preconcentration of copper as its pyrocatechol violet complex on Chromosorb 105 for flame atomic absorption spectrometric determinations. J. Hazard Mater. 163: 1298–1302.10.1016/j.jhazmat.2008.07.096Search in Google Scholar PubMed
Chapdelaine, A., Carrier, J.D., Fournier, L., Duhoux, A., and Roberge, P. (2018). Treatment adequacy for social anxiety disorder in primary care patients. PLoS One 13: e0206357, https://doi.org/10.1371/journal.pone.0206357.Search in Google Scholar PubMed PubMed Central
Childs, E., Lutz, J.A., and Wit, H. (2017). Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend. 177: 136–144, https://doi.org/10.1016/j.drugalcdep.2017.03.030.Search in Google Scholar PubMed PubMed Central
Crippa, J.A., Derenusson, G.N., Ferrari, T., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simões, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al.. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25: 121–130, https://doi.org/10.1177/0269881110379283.Search in Google Scholar PubMed
Davies, C., Wilson, R., Appiah-Kusi, E., Blest-Hopley, G., Brammer, M., Perez, J., Murray, R.M., Allen, P., Bossong, M.G., and McGuire, P. (2020). A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl. Psychiatry 10: 311.10.1038/s41398-020-0862-2Search in Google Scholar PubMed PubMed Central
Davies, C., Appiah-Kusi, E., Wilson, R., Blest-Hopley, G., Bossong, M.G., Valmaggia, L., Brammer, M., Perez, J., Allen, P., Murray, R.M., et al.. (2022). Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. 272: 461–475, https://doi.org/10.1007/s00406-021-01318-z.Search in Google Scholar PubMed PubMed Central
De Faria, S.M., Fabrício, D.M., Tumas, V., Castro, P.C., Ponti, M.A., Hallak, J.E., Zuardi, A.W., Crippa, J.A., and Chagas, M.H. (2020). Effects of acute cannabidiol administration on anxiety and tremors induced by Sumulated Public Speaking Test in patients with Parkinson’s disease. J. Psychopharmacol. 34: 189–196, https://doi.org/10.1177/0269881119895536.Search in Google Scholar PubMed
Fusar-Poli, P., Crippa, J.A., Bhattacharyya, S., Borgwardt, S.J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S.A., O’Carrol, C., Atakan, Z., et al.. (2009). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 66: 95–105, https://doi.org/10.1001/archgenpsychiatry.2008.519.Search in Google Scholar PubMed
Gaoni, Y. and Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of Hashish. J. Am. Chem. Soc. 86: 1646–1647.10.1021/ja01062a046Search in Google Scholar
Garakani, A., Murrough, J.W., Freire, R.C., Thom, R.P., Larkin, K., Buono, F.D., and Iosifescu, D.V. (2020). Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front. Psychiatry 11: 595584, https://doi.org/10.3389/fpsyt.2020.595584.Search in Google Scholar PubMed PubMed Central
Gorka, S.M., Fitzgerald, D.A., Wit, H., and Phan, K.L. (2014). Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. Int. J. Neuropsychopharamcol. 28: pyu104.10.1093/ijnp/pyu104Search in Google Scholar PubMed PubMed Central
Guimarães, F.S., Zuardi, A.W., and Graeff, F.G. (1987). Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J. Psychopharmacol. 1: 184–192, https://doi.org/10.1177/026988118700100305.Search in Google Scholar PubMed
Hariri, A.R., Tessitore, A., Mattay, V.S., Fera, F., and Weinberger, D.R. (2002). The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 17: 317–323, https://doi.org/10.1006/nimg.2002.1179.Search in Google Scholar PubMed
Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J. and Welch, S.V.A (Eds.) (2019). Cochrane handbook for systematic reviews of interventions. 2nd ed. John Wiley & Sons, Chichester (UK).10.1002/9781119536604Search in Google Scholar
Hindocha, C., Freeman, T.P., Schafer, G., Gardener, C., Das, R.K., Morgan, C.J., and Curran, H.V. (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomized, double-blind, placebo-controlled study in cannabis users. Eur. Neuropsychopharmacol. 25: 325–334.10.1016/j.euroneuro.2014.11.014Search in Google Scholar PubMed PubMed Central
Iglesias, L.P., Bedeschi, L., Aguiar, D.C., Asth, L., and Moreira, F.A. (2023). Effects of ∆9-THC and type-1 cannabinoid receptor agonists in the elevated plus maze test of anxiety: a systematic review and meta-analysis. Cannabis Cannabinoid Res. 8: 24–33, https://doi.org/10.1089/can.2022.0078.Search in Google Scholar PubMed
Jefferson, J.W. (2001). Social anxiety disorder: more than just a little shyness. Prim. Care Companion J. Clin. Psychiatry 3: 4–9, https://doi.org/10.4088/pcc.v03n0102.Search in Google Scholar PubMed PubMed Central
Johnson, G.A., Guerra, L., and Oxner, A. (2023). A case of panic attacks developing after 10 years of chronic cannabis use in a patient with no prior psychiatric history. Cureus 15: e34197, https://doi.org/10.7759/cureus.34197.Search in Google Scholar PubMed PubMed Central
Khalsa, J.H., Bunt, G., Blum, K., Maggirwar, S.B., Galanter, M., and Potenza, M.N. (2022). Review: cannabinoids as medicinals. Curr. Addict. Rep. 9: 630–646, https://doi.org/10.1007/s40429-022-00438-3.Search in Google Scholar PubMed PubMed Central
Kindred, R. and Bates, G.W. (2023). The influence of the COVID-19 pandemic on social anxiety: a systematic review. Int. J. Environ. Res. Public Health 29: 2362, https://doi.org/10.3390/ijerph20032362.Search in Google Scholar PubMed PubMed Central
Kirschbaum, C., Pirke, K.M., and Hellhammer, D.H. (1993). The ‘Trier social stress test’—a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76–81, https://doi.org/10.1159/000119004.Search in Google Scholar PubMed
Kwee, C., Baas, J.M., van der Flier, F.E., Groenink, L., Duits, P., Eikelenboom, M., van der Veen, D.C., Moerbeek, M., Batelaan, N.M., and Balkom, A.J (2022). Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomized controlled trial. Eur. Neuropsychopharmacol. 59: 58–67.10.1016/j.euroneuro.2022.04.003Search in Google Scholar PubMed
Leigh, E., Chiu, K., and Ballard, E.D. (2023). Social anxiety and suicidality in youth: a systematic review and meta-analysis. Res. Child Adolesc. Psychopathol. 51: 441–454, https://doi.org/10.1007/s10802-022-00996-0.Search in Google Scholar PubMed PubMed Central
Letamendi, A.M., Chavira, D.A., and Stein, M.B. (2009). Issues in the assessment of social phobia: a review. Isr. J. Psychiatry Relat. Sci. 46: 13–24.Search in Google Scholar
Linares, I.M., Zuardi, A.w., Pereira, L.C., Queiroz, R.H., Mechoulam, R., Guimarães, F.S., and Crippa, J.A. (2019). Cannabidiol presents as inverted U-shaped dose-response in a simulated public speaking test. Braz. J. Psychiatry 41: 9–14, https://doi.org/10.1590/1516-4446-2017-0015.Search in Google Scholar PubMed PubMed Central
Masataka, N. (2019). Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front. Psychol. 10: 2466, https://doi.org/10.3389/fpsyg.2019.02466.Search in Google Scholar PubMed PubMed Central
McNair, D.M., Frankenthaler, L.M., Czerlinsky, T., White, T.W., Sasson, S., and Fischer, S. (1982). Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl.) 77: 7–10.10.1007/BF00436092Search in Google Scholar PubMed
Moreira, F.A. and Wotjak, C.T. (2009). Cannabinoids and anxiety. Curr. Top. Behav. Neurosci. 2: 429–450, https://doi.org/10.1007/7854_2009_16.Search in Google Scholar PubMed
Osório, F.L., Crippa, J.A., and Loureiro, S.R. (2012). Instruments for the assessment of social anxiety disorder: validation studies. World J. Psychiatry 2: 83–85, https://doi.org/10.5498/wjp.v2.i5.83.Search in Google Scholar PubMed PubMed Central
Page, N., Hallingberg, B., Brown, R., Lowthian, E., Hewitt, G., Murphy, S., and Moore, G. (2021). Change over time in adolescent smoking, cannabis use and their association: findings from the school health research network in wales. J. Public Health (Oxf.) 43: e620–e628, https://doi.org/10.1093/pubmed/fdaa174.Search in Google Scholar PubMed PubMed Central
Phan, K.L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., and Wit, H. (2008). Cannabinoid modulation of amygdala rectivity to social signals of threat in humans. J. Neurosci. 28: 2313–2319.10.1523/JNEUROSCI.5603-07.2008Search in Google Scholar PubMed PubMed Central
Pruessner, M., Béchard-Evans, L., Boekestyn, L., Iyer, S.N., Pruessner, J.C., and Malla, A.K. (2013). Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophr. Res. 146: 79–86, https://doi.org/10.1016/j.schres.2013.02.019.Search in Google Scholar PubMed
Rocha, M.F., Swain, R., and Campos, M.S. (2019). The role of progress testing tachling medical student anxiety. Clin. Teach. 14: 417–419, https://doi.org/10.1111/tct.13035.Search in Google Scholar PubMed
Rodebaugh, T.L., Holaway, R.M., and Heimberg, R.G. (2004). The treatment of social anxiety disorder. Clin. Psychol. Rev. 24: 883–908, https://doi.org/10.1016/j.cpr.2004.07.007.Search in Google Scholar PubMed
Sharpe, L., Sinclair, J., Kramer, A., de Manincor, M., and Sarris, J. (2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J. Transl. Med. 18: 374, https://doi.org/10.1186/s12967-020-02518-2.Search in Google Scholar PubMed PubMed Central
Single, A., Bilevicius, E., Ho, V., Theule, J., Buckner, J.D., Mota, N., and Keough, M.T. (2022). Cannabis use and social anxiety in young adulthood: a meta-analysis. Addict. Behav. 129: 107275, https://doi.org/10.1016/j.addbeh.2022.107275.Search in Google Scholar PubMed
Stack, S.K., Wheate, N.J., and Schubert, E.A. (2022). Medicinal cannabis for the treatment of anxiety disorders: a narrative review. Curr. Treat Opt. Psychiatry 9: 163–173, https://doi.org/10.1007/s40501-022-00260-8.Search in Google Scholar
Stein, M.B. and Stein, D.J. (2008). Social anxiety disorder. Lancet 371: 1115–1125.10.1016/S0140-6736(08)60488-2Search in Google Scholar PubMed
Stein, D.J., Scott, K.M., Jonge, P., and Kessler, R. (2017). Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin. Neurosci. 19: 127–136, https://doi.org/10.31887/dcns.2017.19.2/dstein.Search in Google Scholar
Tepe, E., Darlrymple, K., and Zimmerman, M. (2012). The impact pf comorbid cannabis use disorders on the clinical presentation of social anxiety disorder. J. Psychiatr. Res. 46: 50–56, https://doi.org/10.1016/j.jpsychires.2011.09.021.Search in Google Scholar PubMed
Turner, G., Meagher, W., Willis, C., and Colley, P. (1993). Cascade testing carrier status in cystic fibrosis in a large family. Med. J. Aust. 159: 163–165, https://doi.org/10.5694/j.1326-5377.1993.tb137779.x.Search in Google Scholar PubMed
Zuardi, A.W., Crippa, J.A., Hallak, J.E., and Gorayeb, R. (2013). Human experimental anxiety: actual public speaking induces more intense physiological responses than simulated public speaking. Braz. J. Psychiatry 35: 248–253.10.1590/1516-4446-2012-0930Search in Google Scholar PubMed
Zuardi, A.W., Rodrigues, N.P., Silva, A.L., Bernardo, S.A., Hallak, J.E., Guimarães, F.S., and Crippa, J.A. (2017). Inverted U-shaped dose-response curve of the anxiolytic effects of cannabidiol during public speaking in real life. Front. Pharmacol. 8: 259.10.3389/fphar.2017.00259Search in Google Scholar PubMed PubMed Central
© 2023 Walter de Gruyter GmbH, Berlin/Boston
